Abstract
A method was developed for the preparation of hitherto unknown 1,2,4-triazol-1-yl-substituted glutarimide derivatives, based on the reaction of an α-diazo glutarimide reagent with azlactones generated in situ from N-acyl-α-amino acids. This base-catalyzed cyclocondensation provides good-to-high yields of the triazole-glutarimide dyads under mild conditions and allows for broad variation of substituents at both positions of the triazole ring. Following deprotection of the imide NH group, evaluation of the cytotoxicity of the resulting glutarimides against human multiple myeloma cells and peripheral blood mononuclear cells showed no significant effect on viability, indicating a favorable safety profile compared to known cereblon (CRBN) ligands of the immunomodulatory imide drug (IMiD) class.